Reviewing RadNet (RDNT) & Its Competitors

RadNet (NASDAQ:RDNT) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its rivals? We will compare RadNet to related companies based on the strength of its dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for RadNet and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	1	0	6	2	3.00
RadNet Competitors	1863	7734	13360	822	2.55

RadNet presently has a consensus target price of $90.43, indicating a potential upside of 16.02%. As a group, “Healthcare Providers & Services” companies have a potential upside of 12.99%. Given RadNet’s stronger consensus rating and higher possible upside, analysts clearly believe RadNet is more favorable than its rivals.

Volatility and Risk

RadNet has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, RadNet’s rivals have a beta of 0.98, meaning that their average stock price is 2% less volatile than the S&P 500.

Profitability

This table compares RadNet and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RadNet	-0.94%	3.14%	1.08%
RadNet Competitors	-8.06%	-138.13%	-1.54%

Earnings & Valuation

This table compares RadNet and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
RadNet	$2.04 billion	-$18.65 million	-288.67
RadNet Competitors	$21.22 billion	$301.67 million	7.15

RadNet’s rivals have higher revenue and earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

77.9% of RadNet shares are held by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 5.1% of RadNet shares are held by insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

RadNet beats its rivals on 10 of the 13 factors compared.

RadNet Company Profile

RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.